Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 13.75
(1.85%)
SEK 13.75
(1.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -113.32 Million SEK | -2.32% |
| 2022 | -110.75 Million SEK | -34.81% |
| 2021 | -82.16 Million SEK | -103.92% |
| 2020 | -40.29 Million SEK | 12.46% |
| 2019 | -46.02 Million SEK | 46.92% |
| 2018 | -86.7 Million SEK | -28.18% |
| 2017 | -67.64 Million SEK | -29.89% |
| 2016 | -52.07 Million SEK | -60.66% |
| 2015 | -32.41 Million SEK | -425.88% |
| 2014 | -6.16 Million SEK | -19.36% |
| 2013 | -5.16 Million SEK | -146.49% |
| 2012 | -2.09 Million SEK | -117.1% |
| 2011 | -964.98 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.5 Million SEK | 15.14% |
| 2024 Q2 | -23.87 Million SEK | -64.57% |
| 2023 Q4 | -17.09 Million SEK | 26.76% |
| 2023 Q2 | -32.96 Million SEK | 15.95% |
| 2023 FY | -113.32 Million SEK | -2.32% |
| 2023 Q3 | -23.34 Million SEK | 29.19% |
| 2023 Q1 | -39.22 Million SEK | 4.79% |
| 2022 Q4 | -41.19 Million SEK | -42.76% |
| 2022 Q3 | -28.85 Million SEK | -43.27% |
| 2022 Q2 | -20.14 Million SEK | -8.02% |
| 2022 Q1 | -18.64 Million SEK | 17.91% |
| 2022 FY | -110.75 Million SEK | -34.81% |
| 2021 Q3 | -34.46 Million SEK | -197.52% |
| 2021 FY | -82.16 Million SEK | -103.92% |
| 2021 Q1 | -13.27 Million SEK | -34.18% |
| 2021 Q2 | -11.58 Million SEK | 12.73% |
| 2021 Q4 | -22.71 Million SEK | 34.09% |
| 2020 Q1 | -9.64 Million SEK | 20.58% |
| 2020 Q3 | -12.82 Million SEK | -47.08% |
| 2020 Q4 | -9.89 Million SEK | 22.88% |
| 2020 FY | -40.29 Million SEK | 12.46% |
| 2020 Q2 | -8.72 Million SEK | 9.63% |
| 2019 FY | -46.02 Million SEK | 46.92% |
| 2019 Q3 | -8.03 Million SEK | 27.15% |
| 2019 Q4 | -12.14 Million SEK | -51.22% |
| 2019 Q1 | -13.94 Million SEK | 65.34% |
| 2019 Q2 | -11.02 Million SEK | 20.91% |
| 2018 Q1 | -15.1 Million SEK | -0.61% |
| 2018 Q4 | -40.22 Million SEK | -142.44% |
| 2018 Q3 | -16.59 Million SEK | -12.23% |
| 2018 FY | -86.7 Million SEK | -28.18% |
| 2018 Q2 | -14.78 Million SEK | 2.13% |
| 2017 Q3 | -18.33 Million SEK | 1.45% |
| 2017 Q1 | -15.69 Million SEK | 19.19% |
| 2017 Q4 | -15.01 Million SEK | 18.1% |
| 2017 FY | -67.64 Million SEK | -29.89% |
| 2017 Q2 | -18.6 Million SEK | -18.56% |
| 2016 FY | -52.07 Million SEK | -60.66% |
| 2016 Q3 | -14.35 Million SEK | -22.37% |
| 2016 Q4 | -19.41 Million SEK | -35.24% |
| 2016 Q2 | -11.73 Million SEK | -78.51% |
| 2016 Q1 | -6.57 Million SEK | 39.12% |
| 2015 Q2 | -9.94 Million SEK | -237.33% |
| 2015 Q3 | -6.92 Million SEK | 30.3% |
| 2015 Q1 | -2.94 Million SEK | -116.69% |
| 2015 Q4 | -10.79 Million SEK | -55.79% |
| 2015 FY | -32.41 Million SEK | -425.88% |
| 2014 FY | -6.16 Million SEK | -19.36% |
| 2014 Q4 | -1.36 Million SEK | 21.84% |
| 2014 Q3 | -1.74 Million SEK | 2.41% |
| 2014 Q2 | -1.78 Million SEK | -39.3% |
| 2014 Q1 | -1.28 Million SEK | -27.36% |
| 2013 Q4 | -1 Million SEK | 27.12% |
| 2013 FY | -5.16 Million SEK | -146.49% |
| 2013 Q2 | -1.66 Million SEK | -48.35% |
| 2013 Q1 | -1.11 Million SEK | -661.22% |
| 2013 Q3 | -1.37 Million SEK | 16.93% |
| 2012 Q4 | -147 Thousand SEK | 73.42% |
| 2012 Q3 | -553 Thousand SEK | 34.63% |
| 2012 FY | -2.09 Million SEK | -117.1% |
| 2012 Q2 | -846 Thousand SEK | 0.0% |
| 2011 FY | -964.98 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -147.43% |
| Biovica International AB (publ) | -124.82 Million SEK | 9.213% |
| Cantargia AB (publ) | -280.02 Million SEK | 59.531% |
| CombiGene AB (publ) | -35.66 Million SEK | -217.739% |
| Cyxone AB (publ) | -22.98 Million SEK | -392.944% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -870.397% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -591.079% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -23.984% |
| Fluicell AB (publ) | -26.55 Million SEK | -326.764% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 7.918% |
| Mendus AB (publ) | -101.61 Million SEK | -11.518% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -205.692% |
| I-Tech AB | 20.2 Million SEK | 660.922% |
| Intervacc AB (publ) | -102.85 Million SEK | -10.181% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -834.391% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1031.243% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -533.196% |
| OncoZenge AB (publ) | -15.9 Million SEK | -612.634% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -25772.831% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 70.806% |
| Lipum AB (publ) | -37.17 Million SEK | -204.812% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 54.413% |
| Ziccum AB (publ) | -21.41 Million SEK | -429.25% |
| BioArctic AB (publ) | 229.24 Million SEK | 149.432% |
| Genovis AB (publ.) | 61.5 Million SEK | 284.265% |
| Camurus AB (publ) | 431.44 Million SEK | 126.266% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 36.278% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -99.439% |
| Aptahem AB (publ) | -11.11 Million SEK | -919.746% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 63.555% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 36.926% |
| Kancera AB (publ) | -64.88 Million SEK | -74.641% |
| Saniona AB (publ) | -95.81 Million SEK | -18.279% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -168.392% |
| AcouSort AB (publ) | -17.08 Million SEK | -563.134% |
| Xintela AB (publ) | -54.08 Million SEK | -109.535% |
| Abliva AB (publ) | -95.5 Million SEK | -18.652% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2204.029% |
| Amniotics AB (publ) | -30.87 Million SEK | -267.098% |
| 2cureX AB (publ) | -32.51 Million SEK | -248.493% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -783.403% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 75.691% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 86.375% |
| Biosergen AB | -27.03 Million SEK | -319.14% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -585.85% |
| Corline Biomedical AB | -1.8 Million SEK | -6164.4% |
| NextCell Pharma AB | -41.95 Million SEK | -170.075% |
| Nanologica AB (publ) | -75.15 Million SEK | -50.782% |
| LIDDS AB (publ) | -40.2 Million SEK | -181.856% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 65.334% |
| BioInvent International AB (publ) | -330.3 Million SEK | 65.691% |
| SynAct Pharma AB | -215.81 Million SEK | 47.489% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -157.237% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -377.411% |
| Alzinova AB (publ) | -16.48 Million SEK | -587.64% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -3.692% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 54.509% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1041.217% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -437.305% |
| Simris Alg AB (publ) | -37.3 Million SEK | -203.774% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 25.372% |